TCG Crossover

Founder and Managing Partner of TCGX who previously spent sixteen years as Managing Partner at Vivo Capital and held operating roles including COO of Sagent Pharmaceuticals and CBO of China KangHui. He holds an M.D. and M.B.A. from Stanford and a B.A. in Biology from Harvard.

Managing Partner who was previously an Associate at Great Point Partners focused on public therapeutics investments and earlier a healthcare investment banking analyst at Citigroup. He holds a BSc in Biomedical Engineering from Brown University.

Venture Partner leading venture formation, with over 15 years of global healthcare investment and biotech operating experience. She previously served as CBO of ArriVent Biopharma and Managing Director at Vivo Capital, and co-founded RareStone Group.

Analyst in the Bay Area office with a BA in Biology and two years of graduate study in Bioengineering at the University of Pennsylvania. He previously interned at Bank of America and Logos Capital.

Executive Assistant with over two decades of experience in executive support and estate management, having previously worked at the GLIDE Foundation.

Head of Trading who previously worked at Bain Capital Life Sciences on trading and capital markets, founded a multi-billion investment firm, and was a Managing Director at Citigroup Global Markets. He is a Williams College graduate and CFA charterholder.

Science Partner and HHMI Investigator directing the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering, known for work on kinase inhibitors and prostate cancer.

Science Partner and professor at Columbia University Medical Center and HHMI investigator known for sensory neuroscience research, including taste; co-founder of Kallyope.

COO and CFO who previously served as Director of Finance at Vetamer Capital and held COO/CFO/CCO roles at several hedge funds. He is a Canadian Chartered Professional Accountant with a BBA in Accounting from St. Francis Xavier University.

Senior Accounting Manager who previously held accounting manager roles at Spectrum Equity, Makena Capital, and Zuora. She holds an MS from California State University, Los Angeles and a BS in Finance from Renmin University of China.

Listed as the point of contact for investment-related inquiries at TCG Crossover.

Associate (Bioengineer) in the Bay Area office focused on scientific diligence and technical evaluation of drugs. He holds BSc degrees in Bioengineering and Economics from the University of Pennsylvania and Wharton, with prior internships at Novartis and Point72.

Associate who was previously a Senior Associate at Evercore ISI covering SMID cap biotech and a consultant at Eversana Consulting and Deallus. He holds a B.Sc. in Pharmacology from McGill University.

Science Partner and human geneticist, HHMI investigator and professor at UT Southwestern known for work on lipid metabolism and PCSK9; recipient of the Breakthrough Prize in Life Sciences.

Science Partner and professor at Baylor College of Medicine and HHMI investigator known for uncovering the genetic basis of neurological disorders including Rett syndrome.

Controller who previously was a Manager at Standish Management and held accounting roles at Bloom Tree Partners and Davidson Kempner. She holds a BS in Commerce from the University of Virginia.

Operations team member with a background in office administration who previously worked at the Helmsley Charitable Trust and Point72. She holds a BA in International Relations and an MSc in International Development.

Associate who was previously an Associate at New Enterprise Associates focused on private therapeutics investments and earlier a healthcare investment banking analyst at Goldman Sachs. He holds a B.A. in Neuroscience from Northwestern University.

Science Partner who joined 23andMe as chief scientific officer and previously led research at Genentech; a Lasker and Kavli Prize recipient known for work on neurotransmitter release.

Science Partner and molecular biologist known for discovering human transcription factors; he served as President of the Howard Hughes Medical Institute and holds a chair in Biology at UC Berkeley.

Science Partner who is CEO and Chairman of Eikon Therapeutics and formerly President of Merck Research Laboratories and head of R&D at Amgen.

Associate who was previously an Investment Analyst at Foresite Capital Management and an Associate Research Analyst at Eventide Asset Management. He holds a Ph.D. in Chemical Biology from MIT, an M.D. from Harvard Medical School, and a B.S. in Chemistry from MIT.

Science Partner and Vice President of Physiological Chemistry at Genentech, known for foundational research on apoptosis.